On May 23, 2018, we published revised versions of our Privacy Policy and User Agreements. Please read these updated terms and take some time to understand them. Your use of our services is subject to these revised terms.
Yes, I Agree.
Save 20% on Press Releases and More with NNW Prime! Click to View Details
TuesdayNov 15, 2016 1:05 pm

Viking Therapeutics, Inc. (VKTX) Presents Additional Results of VK2809 for Treatment of High Cholesterol; Shares Higher

Viking Therapeutics (NASDAQ: VKTX) is trading higher after the clinical-stage biopharmaceutical company announced additional data from its previously completed phase 1b clinical trial designed to evaluate the safety and tolerability of VK2809 in subjects with mild hypercholesterolemia, or high cholesterol. As presented in a poster presentation earlier this week at the American Heart Association (AHA) Scientific Sessions 2016 in New Orleans, the new results show VK2809's effect on additional proteins associated with cardiovascular disease. "These data support the promise of thyroid beta-targeted approaches for the treatment of cardiovascular and other metabolic diseases.  We previously reported results showing VK2809's ability to…

Continue Reading

TuesdayNov 15, 2016 11:33 am

Fusion Telecommunications (FSNN) Trades Higher on Apptix Acquisition, Q3 Performance, New Credit Facility

Shares of Fusion Telecommunications (NASDAQ: FSNN) are 10% higher after the company announced its acquisition of Virginia-based cloud services provider Apptix, Inc. for $28 million, as well as reported third-quarter revenue of $29.5 million and a $70 million credit facility. Fusion attributes the 20% YoY increase in consolidated revenue to revenue growth of 27% from its Business Services segment. To view the full press release, visit: http://nnw.fm/0zz9C About Fusion Fusion, a leading provider of integrated cloud solutions to small, medium and large businesses, is the industry's single source for the cloud. Fusion's advanced, proprietary cloud service platform enables the integration…

Continue Reading

TuesdayNov 15, 2016 11:31 am

Moxian, Inc. (MOXC) Raises $10M in Public Offering, Uplists to NASDAQ

Moxian, Inc. (NASDAQ: MOXC) this morning made its debut on the NASDAQ Capital Market after a successful uplist from the OTCQB. The provider of an innovative offline-to-online (O2O) integrated social media platform also announced the completion of its public offering, for which it expects gross proceeds of about $10 million. To view the full press release, visit: http://nnw.fm/Rq2EN About Moxian, Inc. Moxian (MOXC) engages in the business of providing social marketing and promotion platforms to merchants who desire to promote their businesses through online social media. The company’s products and services aim to enhance the interaction between users and merchant…

Continue Reading

MondayNov 14, 2016 2:41 pm

NetworkNewsBreaks – Top 10 Mid-day Percentage Gainers on November 14, 2016

Here is a list of stocks shaking up the markets today, with particular focus on NASDAQ and OTC small caps. The top gainers based on percentage: PFTI 42.59% - News: Conversion cuts long-term debt 47% to $7M MCIG 31.53% - News: Turns to profit, Q2 revenues increase 126% from Q1 ENTK 30.77% - News: Inks deal with State Bicycle Co. to build virtual store in Hypatia WARM 20.40% - News: Says Mobile Generation technology is near completion GRWG 28.26% - News: Posts record Q3, nine-month financial results OBCI 18.81% - News: Record Q3 performance; earnings of $1.5M on sales of…

Continue Reading

MondayNov 14, 2016 12:06 pm

Celldex Therapeutics (CLDX): CDX-1140 Data Shows Potential; Shares Climb

Shares of Celldex Therapeutics (NASDAQ: CLDX) are higher Monday morning after the company said it presented data on new product candidate CDX-1140, a fully human antibody targeted to CD40 that has demonstrated potent agonist activity. The data were presented over the weekend at the Society for Immunotherapy of Cancer Annual Meeting (SITC). Key findings include: CDX-1140 binds CD40 with high affinity and specificity and does not block CD40 ligand binding CDX-1140 has an unmodified IgG2 backbone and demonstrates potent agonist activity independent of Fc receptor interactions CDX-1140 demonstrates direct anti-tumor activity in immune-deficient mice challenged with human lymphomas Pharmacological activity…

Continue Reading

MondayNov 14, 2016 12:03 pm

FDA Response Triggers Dynavax Technologies (DVAX) Sell-off

Dynavax Technologies (NASDAQ: DVAX) is down more than 60% mid-morning after the company said it received a Complete Response Letter (CRL) from the FDA regarding its Biologics License Application (BLA) for its HEPLISAV-B™ vaccine against hepatitis B infection. The CRL signals the FDA’s completed a review of an application and stands as a request for additional information for review and approval. Dynavax said it expects a Class 2 designation for a resubmission of the BLA, which would result in a target review period of six months. To view the full press release, visit: http://nnw.fm/9mS6x About Dynavax Dynavax, a clinical-stage biopharmaceutical…

Continue Reading

MondayNov 14, 2016 12:00 pm

National Waste Management Holdings, Inc. (NWMH) is Active Participant in Florida’s Statewide Recycling Initiative

The State of Florida is working toward a statewide recycling goal of 75% by the year 2020. The journey to such a high bar is a lengthy one. While the state’s recycling rate increased by 4% between 2012 and 2013, the amount of solid waste has also increased, from just under 28 million tons to over 30 million. Florida’s Department of Environmental Protection believes that more commercial recycling would help reach its goal of 75%, and National Waste Management Holdings, Inc. (OTC: NWMH) is addressing the challenge head on. Reporting third-quarter revenue growth of 269%, National Waste employs a strategic…

Continue Reading

MondayNov 14, 2016 11:56 am

Acquisition Strategy Sets Medical Transcription Billing Corp. (MTBC) on Pace for Incremental Profits

Recently posting its fourth straight quarter of positive adjusted EBITDA and another quarter of YoY revenue growth, healthcare IT company Medical Transcription Billing, Corp. (NASDAQ: MTBC) (NASDAQ: MTBCP) is demonstrating increased momentum of its aggressive acquisition-based strategy.  The company most recently acquired Texas-based medical billing company MediGain, LLC, including substantially all of its assets and its subsidiary, for $7 million. “In total, the accounts in good standing acquired through this transaction have annual revenues in excess of $10 million … the MediGain acquisition is expected to be accretive to MTBC shareholders in 2017, as incremental profits are expected to greatly…

Continue Reading

FridayNov 11, 2016 1:42 pm

NetworkNewsBreaks – Top 10 Mid-day Percentage Gainers on November 11, 2016

Here is a list of stocks shaking up the markets today, with particular focus on NASDAQ and OTC small caps. The top gainers based on percentage: IMTL 11.10% - News: Collaboration integrates technologies to protect 50 million images DPDW 18.75% - News: Turns to profit in Q3, increases sales GRNH 17.87% - News: Unveils cannabis extraction labs, announces 2017 launch of CBD nutraceutical products MCAP 14.29% - News: Auctioning properties to raise cash and issue dividend EAC 4.18% - News: Bankruptcy Court approves first day motions for Chapter 11 restructuring CLBS 8.17% - News: Q3 revenues increase 58% to $9.3M…

Continue Reading

FridayNov 11, 2016 1:13 pm

Genocea Biosciences, Inc. (GNCA): ATLAS™ Study Demonstrates Potential for Personalized Cancer Vaccines; Shares Climb

Genocea Biosciences (NASDAQ: GNCA) is trading higher after the developer of cell-directed vaccines and immunotherapies reported data supporting the potential of its proprietary antigen identification screening system, ATLAS™, to identify personalized neoantigens that could guide development of neoantigen vaccines. Conducted in collaboration with Memorial Sloan Kettering Cancer Center (MSK), the study analyzed neoantigens in one non-small cell lung cancer patient successfully treated with pembrolizumab (KEYTRUDA®). Data will be presented at the Society for Immunotherapy of Cancer’s (SITC) 31st Annual Meeting & Associated Programs on November 12, 2016. To view the full press release, visit: http://nnw.fm/op5sS About Genocea Genocea is harnessing…

Continue Reading

NetworkNewsWire Currently Accepts

Bitcoin

Bitcoin

Bitcoin Cash

Bitcoin Cash

Ethereum

Ethereum

Litecoin

Litecoin

USD Coin

USD Coin

Contact us: 212.418.1217